Patents by Inventor René Etcheberrigaray
René Etcheberrigaray has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Patent number: 9539235Abstract: The present invention relates to compositions and methods to modulate ?-secretase and/or to improve cognitive ability. The invention further relates the improved/enhanced cognitive ability in diseased individuals, particularly Alzheimer's Disease patients, and treatment thereof through increased sAPP production. Macrocyclic lactones (i.e. bryostatin class and neristatin class) are compounds preferred for use with the present composition. The present invention also provides methods for increasing the generation of non-amyloidogenic soluble APP comprising the activation of protein kinase C (PKC) by administering an effective amount of PKC activator(s).Type: GrantFiled: March 27, 2013Date of Patent: January 10, 2017Assignee: COGNITIVE RESEARCH ENTERPRISES, INCInventors: Rene Etcheberrigaray, Daniel L. Alkon
-
Patent number: 9446020Abstract: The present invention relates to compositions and methods to modulate ?-secretase and/or to improve cognitive ability. The invention further relates the improved/enhanced cognitive ability in diseased individuals, particularly Alzheimer's Disease patients, and treatment thereof through increased sAPP production. Macrocyclic lactones (i.e. bryostatin class and neristatin class) are compounds preferred for use with the present composition. The present invention also provides methods for increasing the generation of non-amyloidogenic soluble APP comprising the activation of protein kinase C (PKC) by administering an effective amount of PKC activator(s).Type: GrantFiled: November 2, 2015Date of Patent: September 20, 2016Assignee: Blanchette Rockefeller Neurosciences InstituteInventors: Rene Etcheberrigaray, Daniel L. Alkon
-
Publication number: 20160051509Abstract: The present invention relates to compositions and methods to modulate ?-secretase and/or to improve cognitive ability. The invention further relates the improved/enhanced cognitive ability in diseased individuals, particularly Alzheimer's Disease patients, and treatment thereof through increased sAPP production. Macrocyclic lactones (i.e. bryostatin class and neristatin class) are compounds preferred for use with the present composition. The present invention also provides methods for increasing the generation of non-amyloidogenic soluble APP comprising the activation of protein kinase C (PKC) by administering an effective amount of PKC activator(s).Type: ApplicationFiled: November 2, 2015Publication date: February 25, 2016Inventors: Rene Etcheberrigaray, Daniel L. Alkon
-
Publication number: 20130281522Abstract: The present invention relates to compositions and methods to modulate ?-secretase and/or to improve cognitive ability. The invention further relates the improved/enhanced cognitive ability in diseased individuals, particularly Alzheimer's Disease patients, and treatment thereof through increased sAPP production. Macrocyclic lactones (i.e. bryostatin class and neristatin class) are compounds preferred for use with the present composition. The present invention also provides methods for increasing the generation of non-amyloidogenic soluble APP comprising the activation of protein kinase C (PKC) by administering an effective amount of PKC activator(s).Type: ApplicationFiled: March 27, 2013Publication date: October 24, 2013Inventors: Rene Etcheberrigaray, Daniel L. Alkon
-
Publication number: 20130072550Abstract: The present disclosure relates to methods of administering compounds for treating conditions associated with amyloid processing such as Alzheimer's Disease. Methods are disclosed comprising the step of administering a macrocyclic lactone, a benzolactam, a pyrrolidinone or a combination thereof to a subject in need in an amount effective to decrease soluble A?-40 or A?-42, or to lower total amyloid precursor protein (“APP”). Methods are also disclosed further comprising the step of identifying a subject with increased soluble A?-40 or A?-42 levels, or elevated APP levels compared to a control population.Type: ApplicationFiled: September 10, 2012Publication date: March 21, 2013Inventors: Rene Etcheberrigaray, Daniel L. Alkon
-
Publication number: 20110196028Abstract: This invention provides a method for isolating and identifying proteins participating in protein-protein interactions in a complex mixture. The method uses a chemically reactive supporting matrix to isolate proteins that in turn non-covalently bind other proteins. The supporting matrix is isolated, and the non-covalently bound proteins are subsequently released for analysis. Because the proteins are accessible to chemical manipulation at both the binding and release steps, identification of the non-covalently bound proteins yields information on specific classes of interacting proteins, such as calcium-dependent or substrate-dependent protein interactions. This permits selection of a subpopulation of proteins from a complex mixture on the basis of specified interaction criteria. The method has the advantage of screening the entire proteome simultaneously, unlike two-hybrid systems or phage display methods which can only detect proteins binding to a single bait protein at a time.Type: ApplicationFiled: June 17, 2010Publication date: August 11, 2011Applicant: BLANCHETTE ROCKEFELLER NEUROSCIENCES INSTITUTEInventors: Rene Etcheberrigaray, Daniel L. Alkon
-
Publication number: 20070037871Abstract: The present invention relates to compositions and methods to modulate ?-secretase and/or to improve cognitive ability. The invention further relates the improved/enhanced cognitive ability in diseased individuals, particularly Alzheimer's Disease patients, and treatment thereof through increased sAPP production. Macrocyclic lactones (i.e. bryostatin class and neristatin class) are compounds preferred for use with the present composition. The present invention also provides methods for increasing the generation of non-amyloidogenic soluble APP comprising the activation of protein kinase C (PKC) by administering an effective amount of PKC activator(s).Type: ApplicationFiled: July 2, 2003Publication date: February 15, 2007Applicant: Blanchette Rockefeller Neurosciences InstiuteInventors: Rene Etcheberrigaray, Daniel Alkon
-
Publication number: 20050037984Abstract: The present invention relates to compositions and methods to modulate ?-secretase and/or to improve cognitive ability. The invention further relates the improved/enhanced cognitive ability in diseased individuals, particularly Alzheimer's Disease patients, and treatment thereof through increased sAPP production. Macrocyclic lactones (i.e. bryostatin class and neristatin class) are compounds preferred for use with the present composition. The present invention also provides methods for increasing the generation of non-amyloidogenic soluble APP comprising the activation of protein kinase C (PKC) by administering an effective amount of PKC activator(s).Type: ApplicationFiled: September 3, 2004Publication date: February 17, 2005Inventors: Rene Etcheberrigaray, Daniel Alkon
-
Patent number: 6825229Abstract: The present invention relates to compositions and methods to modulate &agr;-secretase and/or to improve cognitive ability. The invention further relates the improved/enhanced cognitive ability in diseased individuals, particularly Alzheimer's Disease patients, and treatment thereof through increased sAPP production. Macrocyclic lactones (i.e. bryostatin class and neristatin class) are compounds preferred for use with the present composition. The present invention also provides methods for increasing the generation of non-amyloidogenic soluble APP comprising the activation of protein kinase C (PKC) by administering an effective amount of PKC activator(s).Type: GrantFiled: June 13, 2002Date of Patent: November 30, 2004Assignee: Blanchette Rockefeller Neurosciences InstituteInventors: Rene Etcheberrigaray, Daniel L. Alkon
-
Publication number: 20040019018Abstract: Compounds of the general formula (I): wherein substituents at R1, R2, R3 and R4 have any of the values defined in the specification, and their pharmaceutically acceptable salts, are PKC modulators and are useful for treating diseases, such as, for example, cancers including prostate cancer, inflammatory, autoimmune and neurological disorders including Alzheimer's disease. Also disclosed are pharmaceutical compositions comprising compounds of formula (I), processes for preparing compounds of formula (I), and intermediates useful for preparing compounds of formula (I).Type: ApplicationFiled: July 7, 2003Publication date: January 29, 2004Inventors: Lixin Qlao, Alan Kozikowski, Lianyun Zhao, Rene Etcheberrigaray
-
Publication number: 20030171356Abstract: The present invention relates to compositions and methods to modulate &agr;-secretase and/or to improve cognitive ability. The invention further relates the improved/enhanced cognitive ability in diseased individuals, particularly Alzheimer's Disease patients, and treatment thereof through increased sAPP production. Macrocyclic lactones (i.e. bryostatin class and neristatin class) are compounds preferred for use with the present composition. The present invention also provides methods for increasing the generation of non-amyloidogenic soluble APP comprising the activation of protein kinase C (PKC) by administering an effective amount of PKC activator(s).Type: ApplicationFiled: June 13, 2002Publication date: September 11, 2003Applicant: Neurologic, Inc.Inventors: Rene Etcheberrigaray, Daniel L. Alkon
-
Publication number: 20030108956Abstract: The present invention provides methods for the diagnosis of Alzheimer's disease using human cells. Specifically, one method detects differences between potassium channels in cells from Alzheimer's patient and normal donors, and differences in intracellular calcium concentrations between Alzheimer's and normal cells in response to chemicals known to increase intracellular calcium levels. Other methods detect differences between the memory associated GTP binding Cp20 protein levels between Alzheimer's and normal cells.Type: ApplicationFiled: August 16, 2002Publication date: June 12, 2003Inventors: Daniel L. Alkon, Rene Etcheberrigaray, Christopher S. Kim, Yi-Fan Han, Tom J. Nelson
-
Patent number: 6562783Abstract: The invention provides a compound of formula (I): or salts or hydrates thereof, useful as beta-secretase inhibitors. The invention further relates to a method of reducing plaque formation, particularly useful in the treatment of Alzheimer's disease.Type: GrantFiled: May 30, 2001Date of Patent: May 13, 2003Assignee: Neurologic, Inc.Inventors: Lixin Qiao, René Etcheberrigaray
-
Publication number: 20030078240Abstract: The invention provides a compound of formula (I): 1Type: ApplicationFiled: October 21, 2002Publication date: April 24, 2003Applicant: Neurologic, Inc.Inventors: Rene Etcheberrigaray, Lixin Qiao
-
Publication number: 20030050302Abstract: A method for increasing the generation of non-amyloidogenic soluble APP comprising activation of protein kinase C (PKC) by administering an effective amount of at least one PKC activator. Also provided is a method for altering conditions associated with amyloid processing in order to enhance an &agr;-secretase pathway to generate soluble &agr;-amyloid precursor protein (&agr;-APP) so as to prevent &bgr;-amyloid aggregation comprising administering an effective amount of a benzolactam.Type: ApplicationFiled: September 26, 2002Publication date: March 13, 2003Applicant: Neurologic, Inc.Inventors: Rene Etcheberrigaray, Lixin Qiao, Alan P. Kozikowski
-
Publication number: 20020187928Abstract: The invention provides a compound of formula (I): 1Type: ApplicationFiled: May 30, 2001Publication date: December 12, 2002Inventors: Lixin Qiao, Rene Etcheberrigaray
-
Publication number: 20020098520Abstract: The present invention provides methods for the diagnosis of Alzheimer's disease using human cells. Specifically, one method detects differences between potassium channels in cells from Alzheimer's patient and normal donors, and differences in intracellular calcium concentrations between Alzheimer's and normal cells in response to chemicals known to increase intracellular calcium levels. Other methods detect differences between the memory associated GTP binding Cp20 protein levels between Alzheimer's and normal cells. In addition a diagnostic index for improved assessment between Alzheimer's and non Alzheimer's cells is provided.Type: ApplicationFiled: October 9, 2001Publication date: July 25, 2002Inventors: Daniel L. Alkon, Rene Etcheberrigaray, Christopher S. Kim, Yi-Fan Han, Tom J. Nelson
-
Patent number: 6080582Abstract: The present invention provides methods for the diagnosis of Alzheimer's disease using human cells. Specifically, one method detects differences between potassium channels in cells from Alzheimer's patient and normal donors, and differences in intracellular calcium concentrations between Alzheimer's and normal cells in response to chemicals known to increase intracellular calcium levels. Other methods detect differences between the memory associated GTP binding Cp20 protein levels between Alzheimer's and normal cells.Type: GrantFiled: May 15, 1998Date of Patent: June 27, 2000Assignee: The United States of America as represented by the Department of Health and Human ServicesInventors: Daniel L. Alkon, Rene Etcheberrigaray, Christopher S. Kim, Yi-Fan Han, Tom J. Nelson
-
Patent number: 5976816Abstract: The present invention provides methods for the diagnosis of Alzheimer's disease using human cells. Specifically, one method detects differences between potassium channels in cells from Alzheimer's patient and normal donors, and differences in intracellular calcium concentrations between Alzheimer's and normal cells in response to chemicals known to increase intracellular calcium levels. Other methods detect differences between the memory associated GTP binding Cp20 protein levels between Alzheimer's and normal cells.Type: GrantFiled: September 26, 1994Date of Patent: November 2, 1999Assignee: The United States of America as represented by the Department of Health and Human ServicesInventors: Daniel L. Alkon, Rene Etcheberrigaray, Christopher S. Kim, Yi-Fan Han, Tom J. Nelson
-
Patent number: 5580748Abstract: The present invention is a method for the diagnosis of Alzheimer's disease using human cells. Specifically, the method detects differences between potassium channels in cells from Alzheimer's patient and normal donors, and differences in intracellular calcium concentrations between Alzheimer's and normal cells in response to chemicals known to increase intracellular calcium levels.Type: GrantFiled: May 3, 1993Date of Patent: December 3, 1996Assignee: The United States of America as represented by the Department of Health and Human ServicesInventors: Daniel L. Alkon, Rene Etcheberrigaray, Etsuro Ito, Gary E. Gibson